- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Day 1 Recap: SBS 2025
Author(s):
Key Takeaways
- The South Beach Symposium is a key dermatology conference, fostering education and innovation, as emphasized by Michael Gold, MD.
- Glynis Ablon, MD, highlights the importance of clinical trials in advancing drug and technology discoveries, benefiting both patients and clinicians.
Catch up on coverage from the first day of the 2025 South Beach Symposium held in Miami Beach, Florida.
To stay informed with the latest conference insights, subscribe to receive our eNewsletters.
Michael Gold, MD, on the Energy, Excitement, and Innovation of South Beach Symposium
The South Beach Symposium (SBS) is more than just a dermatology conference—it's a legacy meeting that continues to set the standard for education and innovation in the field, according to Michael Gold, MD, a board-certified dermatologist based in Nashville, Tennessee.
In a recent conversation with Dermatology Times, Gold shared his enthusiasm for the annual event, which has long been a highlight for dermatologists looking to stay at the forefront of the specialty.
Glynis Ablon, MD, on Getting Involved in Clinical Trials
During her talk at SBS 2025, Ablon covered all aspects of clinical trials, including creating a budget, recruiting patients, and analyzing results.
“When you get involved in clinical trials, there are many different aspects that make it a big deal to your own practice,” Ablon said in an interview with Dermatology Times. “Research is at the forefront of new discoveries in drugs and technologies. Running these clinical trials can really provide many of your patient who are difficult or non-responsive to other procedures or treatments these novel therapies, novel treatments, that can actually work for them.”
Ablon noted that, although helpful for non-responsive or difficult cases, being involved in clinical trials is also a great experience for clinicians.
Beyond Topicals: Surgical Solutions for Vitiligo
Nada Elbuluk, MD, MSc, an associate professor of dermatology at the University of Southern California and founding director of their Skin of Color and Pigmentary Disorders Program, provided valuable insights into procedural treatments for vitiligo.
Elbuluk emphasized that "medical treatments for vitiligo are still our first- and second-line therapy," reinforcing the importance of topical immunosuppressive agents, such as corticosteroids, calcineurin inhibitors, and JAK inhibitors, often in combination with phototherapy. These remain the primary treatment strategies for managing active vitiligo. However, when patients exhibit refractory disease—either failing to respond adequately or plateauing in their progress—alternative interventions may be necessary.
Tips and Tricks for Successful Practice Management with Leon Kircik, MD
Leon Kircik, MD, clinical professor of dermatology at Icahn School of Medicine at Mount Sinai in New York City and Indiana University School of Medicine, shared his perspectives on optimizing patient care and managing a successful dermatology practice. With extensive experience in both academia and private practice, Kircik provided valuable insights into time management, practice efficiency, and the integration of clinical trials into medical practice during an interview with Dermatology Times.
